APLS240719C70000
- 0.02
- -0.08-80.00%
Apellis Pharmaceuticals Newsroom
Jefferies Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Analyst Ratings
Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $77
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Analyst Ratings
Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $40 From $50, Maintains Neutral Rating
Piper Sandler Initiates Coverage On Apellis Pharmaceuticals With Neutral Rating, Announces Price Target of $46
Apellis Pharmaceuticals Analyst Ratings
Apellis Pharmaceuticals Analyst Ratings
HC Wainwright & Co. : Apellis Pharmaceuticals (APLS.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $92.00 to $92.00.
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)
Apellis Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60
HC Wainwright & Co. : Apellis Pharmaceuticals (APLS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $92.00.
Apellis Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target